GSK Switch Success: Paxil CR Has 31% Of New Scripts; Augmentin ES, 49%
Executive Summary
GlaxoSmithKline has converted 31% of Paxil new prescriptions to the controlled-release version
You may also be interested in...
GSK Wellbutrin XL Approval Pressures Generics to Launch SR Formulation
The approval of GlaxoSmithKline's Wellbutrin XL puts pressure on generic firms to launch their sustained-release versions of the antidepressant
GSK Wellbutrin XL Approval Pressures Generics to Launch SR Formulation
The approval of GlaxoSmithKline's Wellbutrin XL puts pressure on generic firms to launch their sustained-release versions of the antidepressant
GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals
GlaxoSmithKline's delisting of three Paxil patents will clear the way for approval of generic versions of the antidepressant, and set up a potential dispute over how 180-day exclusivity will be awarded